tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target on Favorable Risk‑Reward and Alzheimer’s Pipeline Upside
PremiumRatingsAnalyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target on Favorable Risk‑Reward and Alzheimer’s Pipeline Upside
5d ago
Video: Jefferies more bullish on Ford and GM
Premium
The Fly
Video: Jefferies more bullish on Ford and GM
5d ago
Morning Movers: Ensign Group surges following second quarter results
Premium
The Fly
Morning Movers: Ensign Group surges following second quarter results
5d ago
MapLight Therapeutics price target raised to $52 from $48 at UBS
PremiumThe FlyMapLight Therapeutics price target raised to $52 from $48 at UBS
12d ago
BMO starts MapLight at Outperform, eyes validation data in August
Premium
The Fly
BMO starts MapLight at Outperform, eyes validation data in August
12d ago
MapLight Therapeutics initiated with an Outperform at BMO Capital
Premium
The Fly
MapLight Therapeutics initiated with an Outperform at BMO Capital
12d ago
MapLight Shareholders Back Board Slate and Auditor
PremiumCompany AnnouncementsMapLight Shareholders Back Board Slate and Auditor
1M ago
MapLight Therapeutics price target lowered to $40 from $43 at Craig-Hallum
Premium
The Fly
MapLight Therapeutics price target lowered to $40 from $43 at Craig-Hallum
1M ago
Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained
Premium
Ratings
Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100